scholarly journals 2172. True Positivity of Common Blood Culture Contaminants among Pediatric Hospitalizations in the United States, 2009–2016

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S737-S737
Author(s):  
Alicen B Spaulding ◽  
David Watson ◽  
Jill Dreyfus ◽  
Phillip Heaton ◽  
Anupam Kharbanda
Keyword(s):  
United States ◽  
Blood Culture ◽  
Pediatric Patients ◽  
Clinical Care ◽  
Laboratory Data ◽  
The United States ◽  
Multivariable Logistic Regression Model ◽  
Coagulase Negative Staphylococci ◽  
Healthcare Database ◽  
Patients Âgés

Abstract Background Distinguishing blood culture (BC) results between common contaminants (CC) and truly pathogenic organisms can be challenging, especially among pediatric patients, but is important for effective clinical care. However, no recent studies have analyzed the true positivity of common BC contaminants in pediatric patients using linked laboratory data from a large national sample of United States hospitals. Methods We conducted a retrospective cohort study among patients ages < 19 using the Premier Healthcare Database (2009–2016), limiting to hospitals reporting ≥ 4 years of BC data and encounters with one of the five most frequent CC among laboratory-confirmed BC. True positivity was defined for each CC as a second positive BC within 48 hours among all BCs. A multivariable logistic regression model including all variables significant in univariate analyses was created comparing encounters: (1) with and without a second BC; and (2) second BC positive vs. negative, with corresponding adjusted odds ratios (aOR) and 95% confidence intervals (CI) reported. Results A total of 5056 isolates corresponding to 4915 encounters with a CC were included in this analysis; 3075 (61%) isolates had a second BC within 48 hours. Adjusted odds of a second BC were higher for encounters from urban (aOR: 1.73, 95% CI: 1.31, 2.29) and ≥ 500 bed hospitals (aOR 1.40, 95% CI: 1.20,1.63). True positivity was 20.2% for coagulase-negative staphylococci (CoNS), 5.9% for Bacillus spp., 5.2% for Viridans group streptococci, 5.0% for Diphtheroids spp., and 3.1% for Micrococcus spp. True positivity for CoNS was higher among neonates but all other organisms were higher for non-neonates (figure). Adjusted odds of true positivity were higher for encounters with chronic conditions (OR 1.44, 95% CI: 1.13, 1.82), a central line in place (OR: 1.65, 95% CI: 1.30, 2.10), per length of stay day (OR: 1.01 (1.01, 1.01), and with an intensive care unit admission (OR: 1.39, 95% CI: 1.08, 1.77). Conclusion True positivity varied substantially by organism, and in most cases was higher among non-neonates. Regional variations for conducting a second BC within 48 hours were found, and more seriously ill patient encounters were more likely to have a common contaminant be pathogenic. Disclosures All authors: No reported disclosures.

Associations of Antimicrobial-Resistant Gram-Negative Bloodstream Infections with Outcomes among Hospitalized Pediatric Patients in the United States

2021 ◽  
Author(s):  
Alicen Burns Spaulding ◽  
David Watson ◽  
Jill Dreyfus ◽  
Phillip Heaton ◽  
Christina Koutsari ◽  
...  
Keyword(s):  
United States ◽  
Retrospective Cohort ◽  
Pediatric Patients ◽  
Bloodstream Infections ◽  
The United States ◽  
Healthcare Database ◽  
Gram Negative ◽  
Drug Classes ◽  
Antibiotic Drug ◽  
The Impact

Abstract Objective The aim of this study was to assess the impact of pediatric antimicrobial-resistant gram-negative bloodstream infections (GNBSIs). Methods A retrospective cohort study (2009–2016) was conducted using the Premier Healthcare Database among pediatric admissions with GNBSIs at hospitals reporting microbiology data. Infections for neonates and nonneonates were classified as multidrug resistance (MDR), resistant to one or two antibiotic drug classes (1–2DR), or susceptible. Results Among 1,276 GNBSIs, 266 (20.8%) infections were 1–2DR and 23 (1.8%) MDR. Compared with susceptible GNBSIs, MDR nonneonates had higher mortality and higher costs, whereas 1–2DR neonates had longer stays and higher costs. Conclusions Antimicrobial-resistant GNBSIs were associated with worse outcomes among pediatric hospitalized patients.

scholarly journals 2851. Impact of Antimicrobial-Resistant Gram-Negative Bloodstream Infections on Outcomes Among Pediatric Hospitalizations in the United States, 2009–2016

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S73-S73
Author(s):  
Alicen B Spaulding ◽  
David Watson ◽  
Jill Dreyfus ◽  
Phillip Heaton ◽  
Anupam Kharbanda
Keyword(s):  
United States ◽  
Susceptibility Testing ◽  
Hospital Admissions ◽  
Bloodstream Infections ◽  
Healthcare Facility ◽  
The United States ◽  
Healthcare Database ◽  
Gram Negative ◽  
Patients Âgés ◽  
The Impact

Abstract Background Antimicrobial-resistant (AMR) Gram-negative bloodstream infections (GNBSIs) are more challenging to treat and may be associated with higher rates of morbidity and mortality. However, no recent studies have assessed the impact of pediatric AMR GNBSIs on outcomes. This study’s objective was to analyze the impact of AMR GNBSIs on mortality, length of stay (LOS), and costs among pediatric hospital admissions in the United States. Methods We conducted a retrospective cohort study of patients ages < 19 from the Premier Healthcare Database (2009–2016) limited to hospitals reporting ≥4 years of blood culture data and to encounters with susceptibility testing among the five most common laboratory-confirmed GNBSIs. AMR was defined per pathogen according to Centers for Disease Control and Prevention criteria. Outcomes mortality, LOS, and total patient encounter costs were compared between AMR and susceptible GNBSIs using Bayesian hierarchical regression modeling, which allowed us to analyze outcomes at the pathogen-level and to incorporate adjustment for confounding factors in order to produce risk-adjusted average differences or risk ratios (RR), and corresponding 95% credible intervals (CrI). Results Among 1,279 GNBSI encounters with susceptibility testing from 104 hospitals, 153 (12%) were AMR, but varied by pathogen. AMR GNBSI occurred more often among non-neonates (62% vs. 51%); non-neonates more often had hospital-acquired infections (27% vs. 13%) or were transferred from a healthcare facility (16% vs. 10%) vs. susceptible GNBSIs. The adjusted RR for mortality was 1.31 (95% CrI 0.62, 3.07) and adjusted average differences for LOS were 6.8 days (95% CrI: −0.3, 16.3) and for cost $23800 (95% CrI $400, $53900) comparing AMR to susceptible GNBSIs. Conclusion This study analyzed the impact of AMR GNBSIs, which were rare, on pediatric patient outcomes using laboratory-confirmed GNBSIs with susceptibility results and advanced statistical methods, finding the greatest impact of pediatric AMR on costs. Knowing the impact of AMR GNBSIs can help improve management of these serious infections, increase clinician and patient awareness of the issue, and further strengthen evidence for justifying pediatric antimicrobial stewardship. Disclosures All Authors: No reported Disclosures.

scholarly journals 2463. Increased Rates of Candida Bloodstream Infections Associated with Drug Use, United States 2012–2017

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S852-S853
Author(s):  
Natalie McCarthy ◽  
James Baggs ◽  
Kelly M Hatfield ◽  
Hannah Wolford ◽  
Snigdha Vallabhaneni ◽  
...  
Keyword(s):  
United States ◽  
Drug Use ◽  
Fungal Infections ◽  
Bloodstream Infections ◽  
The United States ◽  
Diagnostic Code ◽  
Healthcare Database ◽  
Patients Âgés ◽  
Opioid Crisis ◽  
Increased Risk

Abstract Background Opioid misuse is epidemic in the United States (US), and persons who inject drugs are at increased risk for serious bacterial and fungal infections, including Candida bloodstream infections. Historically, candidemia has occurred almost exclusively among patients with severe underlying illness and extensive healthcare exposure. We examined whether the opioid crisis may be having an impact on the epidemiology of candidemia in the United States. Methods Using data from 200 US hospitals reporting to the Premier Healthcare Database (PHD) between 2012–2017, we conducted a retrospective study among hospitalized persons ≥ 18 years. Candidemia was defined by any blood culture yielding Candida species. Drug use-associated (DUA)-candidemia hospitalizations were defined as hospitalizations having both candidemia and at least one ICD-9-CM or ICD-10-CM diagnostic code for recreational drug use; drugs were classified as opioids, cocaine, amphetamines, or other drugs (excluding cannabis, alcohol, and nicotine). We described the characteristics and annual trends of candidemia hospitalizations, stratified by drug use. Results Of 7,590 candidemia hospitalizations during 2012–2017, 679 (9%) were DUA-candidemia. During this time, the rate of DUA-candidemia increased from 3.6 to 9.1 per 100,000 hospitalizations, while the rate of non-DUA-candidemia decreased from 64.7 to 55.6 per 100,000 hospitalizations. Patients with DUA-candidemia were younger (median 40 vs. 64 years), had a longer lengths of stay (median 14 vs. 13 days), and had lower in-hospital mortality (12% vs. 26%). Among DUA-candidemia hospitalizations, opioids accounted for 78% of substances identified. Among patients aged 18–44 years, the proportion of candidemia hospitalizations associated with drug use more than tripled from 13% in 2012 to 44% in 2017 (Figure 1). Conclusion DUA-candidemia hospitalizations increased almost 3-fold during 2012–2017, with drug use identified in nearly half of candidemia patients ages 18–44 years in 2017. These data suggest that the opioid crisis is having an impact on the epidemiology of candidemia in the United States, especially among young adults, underscoring an additional negative consequence of the ongoing crisis. Disclosures All authors: No reported disclosures.

scholarly journals Abortion attempts without clinical supervision among transgender, nonbinary and gender-expansive people in the United States

2021 ◽  
pp. bmjsrh-2020-200966
Author(s):  
Heidi Moseson ◽  
Laura Fix ◽  
Caitlin Gerdts ◽  
Sachiko Ragosta ◽  
Jen Hastings ◽  
...  
Keyword(s):  
United States ◽  
Clinical Supervision ◽  
Online Survey ◽  
Clinical Care ◽  
Insurance Coverage ◽  
Health Insurance Coverage ◽  
The United States ◽  
Physical Trauma ◽  
Abortion Care ◽  
And Gender

BackgroundTransgender, nonbinary and gender-expansive (TGE) people face barriers to abortion care and may consider abortion without clinical supervision.MethodsIn 2019, we recruited participants for an online survey about sexual and reproductive health. Eligible participants were TGE people assigned female or intersex at birth, 18 years and older, from across the United States, and recruited through The PRIDE Study or via online and in-person postings.ResultsOf 1694 TGE participants, 76 people (36% of those ever pregnant) reported considering trying to end a pregnancy on their own without clinical supervision, and a subset of these (n=40; 19% of those ever pregnant) reported attempting to do so. Methods fell into four broad categories: herbs (n=15, 38%), physical trauma (n=10, 25%), vitamin C (n=8, 20%) and substance use (n=7, 18%). Reasons given for abortion without clinical supervision ranged from perceived efficiency and desire for privacy, to structural issues including a lack of health insurance coverage, legal restrictions, denials of or mistreatment within clinical care, and cost.ConclusionsThese data highlight a high proportion of sampled TGE people who have attempted abortion without clinical supervision. This could reflect formidable barriers to facility-based abortion care as well as a strong desire for privacy and autonomy in the abortion process. Efforts are needed to connect TGE people with information on safe and effective methods of self-managed abortion and to dismantle barriers to clinical abortion care so that TGE people may freely choose a safe, effective abortion in either setting.

Use of Temporary Enteral Access Devices in Hospitalized Neonatal and Pediatric Patients in the United States

2015 ◽  
Vol 40 (4) ◽  
pp. 574-580 ◽  
Author(s):  
Beth Lyman ◽  
Carol Kemper ◽  
LaDonna Northington ◽  
Jane Anne Yaworski ◽  
Kerry Wilder ◽  
...  
Keyword(s):  
United States ◽  
Pediatric Patients ◽  
The United States ◽  
Enteral Access

scholarly journals Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States.

1996 ◽  
Vol 40 (4) ◽  
pp. 891-894 ◽  
Author(s):  
G V Doern ◽  
M J Ferraro ◽  
A B Brueggemann ◽  
K L Ruoff
Keyword(s):  
United States ◽  
Antimicrobial Resistance ◽  
Blood Culture ◽  
Rank Order ◽  
The United States ◽  
Medical Centers ◽  
Streptococcus Milleri ◽  
Intermediate Resistance ◽  
High Level ◽  
Viridans Group Streptococci

Three hundred fifty-two blood culture isolates of viridans group streptococci obtained from 43 U.S. medical centers during 1993 and 1994 were characterized. Included were 48 isolates of "Streptococcus milleri," 219 S. mitis isolates, 29 S. salivarius isolates, and 56 S. sanguis isolates. High-level penicillin resistance (MIC, > or = 4.0 micrograms/ml) was noted among 13.4% of the strains; for 42.9% of the strains, penicillin MICs were 0.25 to 2.0 micrograms/ml (i.e., intermediate resistance). In general, amoxicillin was slightly more active than penicillin. The rank order of activity for five cephalosporins versus viridans group streptococci was cefpodoxime = ceftriaxone > cefprozil = cefuroxime > cephalexin. The percentages of isolates resistant (MIC, > or = 2 micrograms/ml) to these agents were 15, 17, 18, 20, and 96, respectively. The rates of resistance to erythromycin, tetracycline, and trimethoprim-sulfamethoxazole were 12 to 38%. Resistance to either chloramphenicol or ofloxacin was uncommon (i.e., < 1%). In general, among the four species, S. mitis was the most resistant and "S. milleri" was the most susceptible.

scholarly journals An overview of nosocomial infections, including the role of the microbiology laboratory.

1993 ◽  
Vol 6 (4) ◽  
pp. 428-442 ◽  
Author(s):  
T G Emori ◽  
R P Gaynes
Keyword(s):  
Antimicrobial Agent ◽  
Nosocomial Infections ◽  
Laboratory Data ◽  
Bloodstream Infections ◽  
Control Program ◽  
The United States ◽  
Microbiology Laboratory ◽  
Coagulase Negative Staphylococci ◽  
Infection Control Program ◽  
Active Involvement

An estimated 2 million patients develop nosocomial infections in the United States annually. The increasing number of antimicrobial agent-resistant pathogens and high-risk patients in hospitals are challenges to progress in preventing and controlling these infections. While Escherichia coli and Staphylococcus aureus remain the most common pathogens isolated overall from nosocomial infections, coagulase-negative staphylococci (CoNS), organisms previously considered contaminants in most cultures, are now the predominant pathogens in bloodstream infections. The growing number of antimicrobial agent-resistant organisms is troublesome, particularly vancomycin-resistant CoNS and Enterococcus spp. and Pseudomonas aeruginosa resistant to imipenem. The active involvement and cooperation of the microbiology laboratory are important to the infection control program, particularly in surveillance and the use of laboratory services for epidemiologic purposes. Surveillance is used to identify possible infection problems, monitor infection trends, and assess the quality of care in the hospital. It requires high-quality laboratory data that are timely and easily accessible.

scholarly journals 2765. Pediatric Mumps during the 2015–2017 Mumps Resurgence in the United States

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S975-S975
Author(s):  
Mariel Marlow ◽  
John Zhang ◽  
Nakia S Clemmons ◽  
Mona Marin ◽  
Manisha Patel ◽  
...  
Keyword(s):  
United States ◽  
Children And Adolescents ◽  
Surveillance System ◽  
Pediatric Patients ◽  
Age Groups ◽  
Exposure Period ◽  
The United States ◽  
College Campuses ◽  
Control And Prevention ◽  
Low Rate

Abstract Background Numerous mumps outbreaks occurred in the United States over the last decade, with outbreaks affecting young adults on college campuses being among the largest and most widely publicized. However, at least half of mumps cases and outbreaks occurred in other age-groups and settings. We describe reported mumps cases among children and adolescents during 2015 through 2017. Methods The Centers for Disease Control and Prevention (CDC) analyzed reports of confirmed and probable mumps cases in persons aged ≤18 years (defined here as pediatric mumps) transmitted electronically through the Nationally Notifiable Diseases Surveillance System (NNDSS) by the 52 reporting jurisdictions. Results Between January 1, 2015 and December 31, 2017, 49 jurisdictions reported 4,886 pediatric mumps cases (35% of all US reported cases, 13,807); 8 jurisdictions reported >100 cases each, representing 82% of all pediatric cases. Overall, 29 (1%) cases were in infants <1 yr, 406 (8%) were in children aged 1–4 years, 1,408 (29%) in children aged 5–10 years, 1,365 (28%) in adolescents aged 11–14 years, and 1,678 (34%) in adolescents aged 15–18 years. Most (3,548, 73%) cases did not travel outside the state during their exposure period; only 37 (1%) traveled outside the country. Cases in patients aged 1–4 years were more frequently non-outbreak associated (38%) than those in patients <1 years and 5–18 years (24% and 9%, respectively). Among 3,309 (68%) patients with known number of MMR doses received, 81% of those 5–18 years had ≥2 MMR doses, while 67% of those 1–4 years had ≥1 dose. Median time since last MMR dose for patients with 2 doses was 8 years (IQR: 4, 11 years). Four patients had meningitis and 1 had encephalitis; all were ≥10 years old and previously received 2 MMR doses. Of male mumps patients older than 10 years of age (2,113), 46 (2%) reported having orchitis; of these, 33 (72%) had 2 MMR doses. Sixty-four patients were hospitalized and there were no deaths. Conclusion About one-third of cases reported during the recent US mumps resurgence were in children and adolescents. The low rate of mumps complications compared with previous studies suggests mumps complications may not be adequately captured in national surveillance or identified by providers. Providers should remain vigilant that mumps can still occur among fully vaccinated pediatric patients, even those recently vaccinated. Disclosures All authors: No reported disclosures.

Sign in / Sign up

Export Citation Format

Share Document